This article showcases a curated list of standout studies over the last week on topics such as cholesterol, GLP-1 drugs for ...
Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...
GLP-1 medications initially were used to help people with diabetes improve their insulin resistance and hunger cravings.
Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...
The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy.
Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.
In the first year after glucagon-like peptide-1 receptor agonist initiation, thyroid cancer risk was elevated. HealthDay News — The absolute risk for thyroid cancer is low among patients receiving ...
HealthDay News — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published online Jan. 16 ...
Q3 2024 results showed net income of $45.9 million, up 71% year-over-year, along with EBITDA of $119.1 million, up 55% year-over-year. Gross profit also rose to $286 million. GLP increased its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results